WHO strategies for the management of drug-resistant tuberculosis
Arch Bronconeumol. 2017 Mar;53(3):95-97.
doi: 10.1016/j.arbres.2016.07.015.
Epub 2016 Oct 4.
[Article in
English,
Spanish]
Affiliations
- 1 Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias, Hospital Universitario de Monterrey, Monterrey, Nuevo León, México.
- 2 World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italia.
- 3 World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italia; Public Health Consulting Group, Lugano, Suiza.
- 4 World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italia. Electronic address: giovannibattista.migliori@fsm.it.
No abstract available
MeSH terms
-
Antitubercular Agents / therapeutic use*
-
Extensively Drug-Resistant Tuberculosis / diagnosis
-
Extensively Drug-Resistant Tuberculosis / drug therapy*
-
Extensively Drug-Resistant Tuberculosis / prevention & control
-
Financial Support
-
Health Services Accessibility
-
Humans
-
Mycobacterium tuberculosis / drug effects
-
Quality of Health Care
-
Tuberculosis, Multidrug-Resistant / diagnosis
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / prevention & control
-
World Health Organization*